Metabolic dysregulation, associated with DUX4 activity, varies between mild and severe FSHD patients, with mild cases exhibiting compensatory mechanisms to mitigate metabolic stress, inflammation, and oxidative damage. The gene discussed is DUX4; the disease is Facioscapulohumeral dystrophy.